CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 444 enrolled / 444 target
Drug / intervention
Atezolizumab +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02839707
NCT02839707Phase 2ActiveUpdate Overdue (4.1/mo)Completion was 37mo ago
CompareCT.gov

A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer

National Cancer Institute (NCI)·interventional·Posted Jul 21, 2016·Updated Jun 29, 2026

In Brief

A Phase 2 clinical trial evaluating Atezolizumab, Bevacizumab, and 3 other interventions for Fallopian Tube High Grade Serous Adenocarcinoma and 18 related conditions. Active but no longer recruiting, targeting 444 participants across 920 sites in 2 countries.

Signals

Enrollment appears stalled

Detailed Summary

This phase II/III trial studies how well pegylated liposomal doxorubicin hydrochloride with atezolizumab and/or bevacizumab work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent). Chemotherapy drugs, such as pegylated liposomal doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. It is not yet known which combination will work better in treating patients with ovarian, fallopian tube, or primary peritoneal cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube Undifferentiated Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Undifferentiated Carcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Undifferentiated Carcinoma
CountriesPuerto Rico, United States
CollaboratorsNRG Oncology

Timeline

Phase 2Active
20172018201920202021202220232024202520262027
First PostedJul 21, 2016
Enrollment StartJun 23, 2017
Primary CompletionMay 9, 2023
Study CompletionMay 11, 2027
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 9.9 years ago

Arms & Interventions

Arm I (PLD, atezolizumab)experimental

Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 and atezolizumab IV over 30-60 minutes on days 1 and 15. (Closed to accrual as of February 09, 2021)

Drug: AtezolizumabProcedure: Computed TomographyDrug: Pegylated Liposomal Doxorubicin HydrochlorideOther: Quality-of-Life Assessment
Arm II (PLD, bevacizumab, atezolizumab)experimental

Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1, bevacizumab IV over 30-90 minutes on days 1 and 15, and atezolizumab IV over 30-60 minutes on days 1 and 15. Patients also undergo CT on study.

Drug: AtezolizumabBiological: BevacizumabProcedure: Computed TomographyDrug: Pegylated Liposomal Doxorubicin HydrochlorideOther: Quality-of-Life Assessment
Arm III (PLD, bevacizumab)active_comparator

Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 and bevacizumab IV over 30-90 minutes on days 1 and 15. Patients also undergo CT on study.

Biological: BevacizumabProcedure: Computed TomographyDrug: Pegylated Liposomal Doxorubicin HydrochlorideOther: Quality-of-Life Assessment

Interventions

Atezolizumabdrug

Given IV

Bevacizumabbiological

Given IV

Computed Tomographyprocedure

Undergo CT

Pegylated Liposomal Doxorubicin Hydrochloridedrug

Given IV

Quality-of-Life Assessmentother

Ancillary studies